PROXY STATEMENT

Company

Cadrenal Therapeutics, Inc.

Filed

July 31, 2025

Period of Report

September 24, 2025

Accession Number

0001213900-25-069612

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →